Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System.

HOME
>
論文・技術情報
>
Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System.

アブストラクト
ジャーナル名	Diabetes care
Pubmed追加日	2018/12/12
投稿者	Wang, Tiansheng; Lu, Wenchao; Tang, Huilin; Buse, John B; Sturmer, Til; Gower, Emily W
組織名	Department of Epidemiology, Gillings School of Global Public Health, University;of North Carolina at Chapel Hill, Chapel Hill, NC tianwang@unc.edu.;Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital,;Capital Medical University), Beijing, China.;Department of Pharmacy Administration and Clinical Pharmacy, School of;Pharmaceutical Sciences, Peking University, Beijing, China.;Institute for Drug Evaluation, Peking University Health Science Center, Beijing,;China.;Department of Medicine, University of North Carolina School of Medicine, Chapel;Hill, NC.;of North Carolina at Chapel Hill, Chapel Hill, NC.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/30530488/